Dataset opportunity
Docobo — Medical Imaging Dataset Opportunity
Large medical imaging dataset held by Docobo, usable for Diagnostic AI and Computer Vision.
Score
48
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
76%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
Global AI in Medical Imaging market was estimated at USD 1.8 billion in 2025, with a projected CAGR of 35.11% (2026-2033) (source: Grand View Research). [1]
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-06-18
Zoll receives FDA warning letter over quality concerns
medtechdive.com ↗ - 📰press2026-06-18
Penumbra wins CE mark for Thunderbolt clot removal tech
medtechdive.com ↗ - 📰press2026-06-18
Kinova launches KIMA medical robotic arm
therobotreport.com ↗ - 📰press2026-06-18
Microbot Medical to expand veteran access to robotic surgery with LIBERTY
therobotreport.com ↗ - 📰press2026-06-17
Distalmotion, in US push, adds more robotic gynecology indications
medtechdive.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- 📦Data product
DOC@HOME platform for longitudinal patient records and clinical analytics
source ↗
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Large
Freshness
Real-time
Rarity
Medium
Accessibility
Restricted
Legal
Largely customer-owned — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Docobo provides a unique Medical Imaging Dataset that is deeply integrated with longitudinal patient records and real-time iot_data, including vital signs. This rich, multi-modal data structure offers a comprehensive view of patient health over time, making it exceptionally valuable for developing and validating high-precision Diagnostic AI models that require deep clinical context beyond static images.
The global market for AI in medical imaging demonstrates significant value, estimated at USD 1.8 billion in 2025 and projected to grow at a remarkable CAGR of 35.11%. [1] Despite complex access negotiations involving NHS information governance and group-level strategy alignment, the rarity and clinical depth of this dataset represent a critical asset for buyers aiming to capture a leading position in this rapidly expanding, high-demand market. [1] ⚠ Diligence (valuable data, access to negotiate): Data is primarily owned by the NHS (customer-owned), requiring complex Information Governance (IG) and secondary use approvals.; Subsidiary of Graphnet Health (part of System C & Graphnet Care Alliance), necessitating group-level data strategy alignment.; Highly sensitive clinical data including longitudinal patient records and real-time vitals. · corporate: acquired of Graphnet Health.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Docobo's deep integration within the UK's NHS, providing access to longitudinal patient records that connect primary care, hospital, and community data for over 800,000 individuals. This is the source of the medical imaging dataset, offering the rich clinical context highly sought after by diagnostic AI companies to train more accurate and robust models. In a global AI medical imaging market projected to grow at over 35% annually, this dataset represents a rare opportunity to acquire images linked to the complete patient journey, a key differentiator for developing next-generation diagnostic AI.
See dimension details ↓- Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity58
proprietary domain data (open lowers rarity)
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume100
9 evidence hits, explicit data-volume mention
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
real-time/streaming
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
Buyer demand is exceptionally high, driven by the explosive growth of the AI in Medical Imaging market, which is forecast to expand at a CAGR of 35.11%. [1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
open/API access
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility17
high difficulty, acquired of Graphnet Health
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength100
6 evidence types, 9 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License0
ownership=customer_owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence45
acquired of Graphnet Health
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 data-appetite signals (1 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 5 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit67
⚠ review — Docobo's core business is selling a remote patient monitoring and population health intelligence platform (DOC@HOME), which is a form of selling intelligence, making it a bad fit. Issues: The company's core product is a software platform (SaaS) that provides analytics and intelligence to healthcare providers. [5, 6, 7]; This is not a case of 'dormant data'; the data collected is actively used to provide the core service for which the company charges. [1, 11, 17]; Docobo was acquired b
- Deep Qualification90
⚠ needs review — The hypothesis is flawed; Docobo is a tooling vendor for remote patient monitoring, not a holder of medical imaging data. The data is owned by its NHS customers and is highly sensitive. [business model = tooling_vendor; data is owned by the company's customers; dataset_type implausible vs real activity: The target's core business is remote patient monitoring (vital signs, symptoms, ECG waveforms) via its DOC@HOME platform, not medical imaging (e.g., X-rays, CT scans). [2, 3, 11]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
This is the core evidence, proving the images are sourced from integrated, longitudinal patient records that combine hospital and GP data, providing the rich clinical context essential for training high-performance diagnostic models.
Event streams
The evidence points to a capability for handling real-time clinical data streams from GP practices, a valuable asset for developing dynamic diagnostic or patient monitoring AI tools.
Public datasets
This shows experience working with large-scale, national UK primary care datasets like CPRD, demonstrating a core competency in navigating the UK's complex healthcare data ecosystem.
IoT / sensor data
Docobo processes high-volume data from remote patient monitoring, indicating access to millions of measurements that can provide valuable temporal context to the imaging data.
Data-volume signal
The platform connects data for over 800,000 people, demonstrating the significant scale required to train and validate AI models that can generalize across a diverse population.
Downloads / exports
These documents confirm a strategic focus on creating shared care records, which is the mechanism that unifies disparate data sources and provides the foundation for this comprehensive dataset.
Coverage
Scanned sources
Deliverable
Premium dataset report
Docobo Medical Imaging — a Large medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market was estimated at USD 1.8 billion in 2025, with a projected CAGR of 35.11% (2026-2033) (source: Grand View Research). [1]. Investment score 48.0/100 (confidence 0.76). Recommended action: Data Sharing Agreement.